Envista (NYSE:NVST) Issues Earnings Results, Beats Estimates By $0.07 EPS

Envista (NYSE:NVST) posted its quarterly earnings results on Wednesday. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.07, FiscalAI reports. The business had revenue of $730.50 million during the quarter, compared to the consensus estimate of $716.11 million. Envista had a return on equity of 7.11% and a net margin of 2.41%.The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 EPS. Envista updated its FY 2026 guidance to 1.500-1.550 EPS.

Here are the key takeaways from Envista’s conference call:

• Strong second-quarter results: Envista delivered 5% core sales growth, 28% adjusted EBITDA growth, 58% adjusted EPS growth to $0.41, and 158% free-cash-flow conversion. Growth was broad-based across both reporting segments and major geographies.
• Full-year guidance was raised and narrowed to 3.5%-4.5% core growth, 11%-14% adjusted EBITDA growth, and adjusted EPS of $1.50-$1.55; the expected tax rate was also reduced to approximately 26% from prior guidance.
• Equipment & Consumables grew 8.5% organically, supported by high-single-digit growth in consumables and diagnostics, continued share gains, pricing, and new products. Spark again grew at a double-digit rate, while new implant, orthodontic, and consumable product launches are intended to support future growth.
• Operational execution continued to improve profitability, with adjusted EBITDA margin expanding 230 basis points to 14.7% through manufacturing productivity, G&A savings, pricing, and favorable volume mix. The company also repurchased approximately 2.4 million shares and ended the quarter with net debt of 0.7 times adjusted EBITDA.
• Management expects slower reported growth in the second half, including flat to slightly negative core growth in the fourth quarter because of four fewer selling days. China’s upcoming ortho and implant volume-based procurement programs are expected to create significant price pressure, including roughly 10%-15% implant price compression and potentially greater pressure in orthodontics.

Envista Trading Down 2.8%

NYSE:NVST traded down $0.80 during midday trading on Thursday, hitting $27.83. The stock had a trading volume of 4,003,999 shares, compared to its average volume of 2,959,525. The stock has a 50-day moving average of $25.87 and a 200 day moving average of $25.99. The company has a market capitalization of $4.53 billion, a price-to-earnings ratio of 67.95, a PEG ratio of 1.58 and a beta of 0.86. Envista has a one year low of $18.77 and a one year high of $30.42. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47.

Hedge Funds Weigh In On Envista

A number of hedge funds and other institutional investors have recently made changes to their positions in NVST. Caitong International Asset Management Co. Ltd lifted its stake in Envista by 16,711.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after acquiring an additional 1,504 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Envista by 73.1% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after purchasing an additional 949 shares during the period. UMB Bank n.a. lifted its position in shares of Envista by 46.1% in the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock worth $44,000 after purchasing an additional 636 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Envista by 378.0% during the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after purchasing an additional 1,909 shares in the last quarter. Finally, Quarry LP purchased a new position in Envista during the third quarter valued at approximately $66,000.

Key Stories Impacting Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Envista reported second-quarter adjusted EPS of $0.41, above the consensus estimate of $0.34 and up from $0.26 a year earlier. Revenue increased 7.1% year over year to $730.5 million, exceeding expectations of $716.1 million. Envista Reports Second Quarter 2026 Results
• Positive Sentiment: The company raised or reaffirmed fiscal 2026 EPS guidance at $1.50–$1.55, above the analyst consensus of approximately $1.43. The outlook suggests continued earnings growth and helped reinforce the positive quarterly results. Envista Q2 Earnings and Revenues Surpass Estimates

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NVST shares. BMO Capital Markets started coverage on Envista in a report on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 target price on the stock. Evercore reiterated an “outperform” rating and issued a $33.00 price target on shares of Envista in a report on Thursday, May 7th. Piper Sandler reiterated a “neutral” rating and issued a $28.00 target price (up from $26.00) on shares of Envista in a research note on Thursday. Wall Street Zen downgraded Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Robert W. Baird set a $34.00 target price on shares of Envista in a research note on Thursday. Six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Envista presently has an average rating of “Hold” and an average price target of $29.31.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.